UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Total Current Liabilities

Last Annual Value

10.74M

3-Year CAGR

30%

5-Year CAGR

17%

10-Year CAGR

8%

UB

Upstream Bio, Inc. Competitors Analysis of Total Current Liabilities

UPB · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.74M
18.1%N/AN/A 
30.73M
47.2%23.1%29.6%
59.77M
56.0%9.2%N/A
37.45M
-12.8%-8.4%N/A
25.58M
-5.5%1.0%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
86.93M
132.5%N/AN/A
62.65M
39.1%N/AN/A
28.95M
24.3%N/AN/A
53.54M
1.5%-8.9%-2.9%
132.04M
50.4%47.5%N/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97